DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report released on Friday morning. The brokerage issued a hold rating on the stock.

Separately, JMP Securities reissued a “market outperform” rating and set a $10.00 price target on shares of DBV Technologies in a research report on Friday, January 10th.

DBV Technologies Stock Down 6.5 %

Shares of NASDAQ:DBVT opened at $4.87 on Friday. The company has a market cap of $100.17 million, a P/E ratio of -1.08 and a beta of 0.71. DBV Technologies has a 52 week low of $2.20 and a 52 week high of $8.32. The business has a fifty day simple moving average of $4.37 and a 200-day simple moving average of $3.81.

Institutional Investors Weigh In On DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC acquired a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies at the end of the most recent reporting period. 71.74% of the stock is owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.